Trial of Bharat Biotech’s Covaxin in the 2-18 years age group is likely to begin in the next 10-12 days. This was stated today by VK Paul, member of NITI Aayog (Health)while speaking to the media today. Drugs Controller General of India (DCGI) had last week approved Covaxin for Phase II/III clinical trials in that age group. Speaking on use of DRDO’s Covid drug 2DG, Paul said “We will examine the drug in Covid-19 National Task Force for adding it to the treatment protocol.” The drug already has DCGI approval for emergency use on Covid patients.
May 19, 2021, 07:57AM ISTSource: Times Now